WHAT'S NEW

WuXi to Build New Cell Therapy Manufacturing Facility for CAR-T Cells and Other Cancer Immunotherapies

WuXi to Build New Cell Therapy Manufacturing Facility for CAR-T Cells and Other Cancer Immunotherapies

We will begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. Read more.

WuXi Cambridge Office Grand Opening

WuXi Cambridge Office Grand Opening

Cars are buried in deep snow, temperature way below freezing point, public transportation paralyzed. Yet, Boston showed once again the can-do attitude and why it has become the most vibrant life science hub of the world. Read more.

Congratulations to Hua Medicine on Filing IND in US for its Novel GKA-based Diabetes Drug

Congratulations to Hua Medicine on Filing IND in US for its Novel GKA-based Diabetes Drug

We are pleased to share with you that our partner, Hua Medicine, has filed an Investigational New Drug (IND) application with the US FDA for its novel 4th-Generation glucokinase activator (GKA) to treat Type 2 diabetes (T2DM).  Read more.

Congratulations to TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S FDA

Congratulations to TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S FDA

We are pleased to share with you that our partner, TaiMed Biologics, has received breakthrough therapy designation from the U.S FDA for ibalizumab.  Read more.

INNOVATION THAT MATTERS

Advances in Targeted Therapies against Lung Cancer

Advances in Targeted Therapies against Lung Cancer

Lung cancer was the leading cause of cancer death worldwide in 2012 according to WHO (World Health Organization, 2012) and the second most commonly diagnosed cancer in both men and women.  Read more.

The First True Anti-Aging Drug?

The First True Anti-Aging Drug?

A clinical trial sponsored by Novartis could potentially unlock the secret of the molecular “fountain of youth” and holds the promise of an effective anti-aging drug. Read more.

Genentech's New Combination Chemotherapy Prolonged Breast Cancer Patient Lives for Extra 16 Months

Genentech's New Combination Chemotherapy Prolonged Breast Cancer Patient Lives for Extra 16 Months

A phase III clinical trial sponsored by Genentech using a combination of chemotherapy drugs showed unprecedented results in patients...Read more.

FDA Approves Lenvima for Treatment of Progressive Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)

FDA Approves Lenvima for Treatment of Progressive Radioiodine-refractory Differentiated Thyroid Cancer 

FDA announced this February the approval of lenvima (lenvatinib), a novel investigative chemotherapy for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Read more.

EVENTS

WuXi’s Dr. Steve Yang to Moderate "Biologics: China's New Wave of Innovation"

WuXi’s Dr. Steve Yang to Moderate "Biologics: China's New Wave of Innovation"

Steve Yang, PhD, Executive Vice-President and COO of WuXi will once again participate in the 2015 edition of the annual ChinaBio Partnering Forum, which will be held April 15-16 in Shanghai.  Read more.

Thank you for your support in helping WuXi reach where we are today. We will continue with our goal - to serve you better with our integrated technology and capability platform.
 Office of Corporate Communications, WuXi AppTec

Web: www.wuxiapptec.com | Email: communications@wuxiapptec.com